On Dec. 12, 2020, Amarin announced clinical results from the CardioLink-9 Trial, the first results of a study of VASCEPAﾮ (icosapent ethyl) in COVID-19 infected outpatients. This randomized trial represented the first human experience with an 8 g/day loading dose of icosapent ethyl and suggested short-term safety and tolerability in a modest sample size.

The study provided the first evidence of potential early anti-inflammatory effect of icosapent ethyl in symptomatic, COVID-19 positive outpatients.